Claim: An experimental personalized mRNA vaccine against pancreatic cancer is keeping nearly 90% of patients whose immune systems responded alive at 6 years post-treatment, suggesting a potential cure for one of the deadliest cancers.

First requested: July 18, 2026 at 9:05 AM
71%

IsItCap Score

Truth Potential Meter

Generally Credible

AI consensusWeak

Grader consensus is weak.
Range 50%–75% (spread Δ25).
The graders diverge. Treat the combined score as uncertain and read the sources carefully.
Read analysis summary

OpenAI Grade

0%
20%
40%
60%
80%
75%

Perplexity Grade

0%
20%
40%
60%
80%
50%

Google Gemini Grade

0%
20%
40%
60%
80%
50%

Analysis Summary

The claim that an experimental personalized mRNA vaccine keeps nearly 90% of patients alive at 6 years post-treatment is mostly true. Reports from reputable sources like ScienceAlert and Memorial Sloan Kettering Cancer Center support this figure, indicating a significant survival rate among immune responders. However, some sources, including The Week, report a slightly lower survival rate of 75%, which introduces some uncertainty regarding the exact percentage. This discrepancy suggests that while the vaccine shows promise, further validation is needed to confirm the extent of its efficacy. The models diverge sharply — treat this as higher-uncertainty. OpenAI comes in highest (75%), while Gemini is lowest (50%). OpenAI expresses higher confidence than Gemini on this claim. While the majority of sources support the claim of nearly 90% survival among immune responders, some reports indicate a lower survival rate of 75%. This variation could stem from differences in study populations or methodologies, which may affect the overall interpretation of the vaccine's effectiveness. The presence of conflicting data does not negate the positive findings but highlights the need for more comprehensive studies to establish a clearer understanding of the vaccine's impact on survival rates in pancreatic cancer patients.
Jump to source analysis

Source quality

Truth (from sources)8.00 / 10
Source reliability8.00 / 10
Source independence7.00 / 10

Claim checks

Fits established facts7.00 / 10
Logical consistency8.00 / 10
Expert consensus7.00 / 10
Related fact checks

Source Analysis

Mainstream Sources

Publication

Memorial Sloan Kettering Cancer Center (Facebook)

Title

Personalized mRNA vaccine shows promise in preventing pancreatic ...

Summary

New results from a phase 1 trial presented at AACR 2026 show nearly 90% of vaccine responders were still alive six years later.

Source details

—

URL

Visit Source

Publication

ScienceAlert

Title

Personalized Vaccine For 'Deadliest Major Cancer' Keeps Patients Alive 6 Years Later

Summary

Researchers reported at a conference that approximately 90 percent of patients who generated an immune response remain alive at the 6-year follow-up.

Source details

—

URL

Visit Source

Publication

IFLScience

Title

New Personalized mRNA Vaccine Keeps Pancreatic Cancer At Bay 6 Years After Treatment

Summary

Follow-up reports state seven of the eight immune responders were still alive between four and six years after receiving the last treatment.

Source details

—

URL

Visit Source

Alternative Sources

Publication

The Week

Title

A new era for pancreatic cancer? Personalised mRNA vaccine shows 6-year survival success

Summary

This source reports that 75% of responders (six patients) are still alive after six years, differing from the nearly 90% figure.

Source details

—

URL

Visit Source

Publication

Pancreatic Cancer Action Network (Facebook)

Title

Pancreatic Cancer Action Network - Facebook

Summary

Dr. Vinod Balachandran reported that seven of eight responders (87.5%) are still alive, which is slightly below the claimed 90%.

Source details

—

URL

Visit Source

Analysis Breakdown

True/False Spectrum (8.0)Source Credibility (8.0)Bias Assessment (7.0)Contextual Integrity (7.0)Content Coherence (8.0)Expert Consensus (7.0)75%

How to read the breakdown

Weakest areas
Independence7.0/10Context7.0/10
  • Truth: how well sources support the core claim.
  • Source reliability: whether the sources have a strong track record.
  • Independence: whether coverage looks one-sided or recycled.
  • Context: missing details (timeframe, definitions, scope) that change meaning.
  • Tip: if graders disagree, rely more on the summary + sources than the single number.

Detailed AnalysisPremium Feature

Get an in-depth analysis of content accuracy, source credibility, potential biases, contextual factors, claim origins, and hidden perspectives.

Create a free account to unlock premium features.

Methodology